Stories
Prime supports initiative to end the HIV epidemic by 2030
Promotes patient access to preventive care from any pharmacy at no cost
August 5, 2021Awareness and prevention prior to exposure are integral in reducing the number of people affected by HIV. In part to support this initiative, the United States Preventive Services Task Force (USPSTF) released an Affordable Care Act (ACA) guideline recommending pre-exposure prophylaxis (PrEP) at no cost to anyone at risk of HIV acquisition.³
To align with this initiative, in July 2020, Prime and its Blue Plan clients introduced ACA HIV PrEP benefits that increased access to PrEP antiretroviral medicines for at-risk people. The updated benefit design leveraged claims data to give doctors and their non-HIV infected patients $0 access to PrEP medications while minimizing disruption in therapy and promoting adherence for members already taking the same medicines for HIV post-exposure prophylaxis or treatment in accordance with their benefits.
Prime also has a number of pharmacy network initiatives, including specific HIV and quality of care networks and maintains contracts with many HIV pharmacies to ensure patient access and support their care needs. Patients are able to use any HIV focused pharmacy or other pharmacies of their choice as part of their benefit.
Prime and its Blue Plan clients are committed to helping in the goal to reduce the incidence of HIV infection.
Overview of Market and Prime Therapeutics’ HIV Spending
*blended PrEP + PEP (Post-Exposure Prophylaxis) + treatment & $0 member spend from ACA or client programs
- https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics
- https://www.cdc.gov/hiv/policies/strategic-priorities/mobilizing/prevention-priorities.html
- https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis
Related news
Stories
July 22, 2024
Introducing the latest issue of our medical and pharmacy benefit management report
The summer 2024 issue of the Magellan Rx Report provides insights on the industry’s most groundbreaking managed care solutions in some of the most complex areas of health care
Stories
July 18, 2024
Specialty drug trend forecasted to drop for employer groups, clinical experts say
Introduction of Humira® and Stelara® biosimilars contribute to continued decline in the autoimmune – anti-inflammatory trend
Stories
July 16, 2024
Prime/Magellan Rx earns top score on the Disability Equality Index
For the second consecutive year, Prime Therapeutics/Magellan Rx Management received a score of 100 on the Disability Equality Index®, which benchmarks disability workplace inclusion